Kyowa Kirin

What Kyowa Kirin does

Kyowa Kirin Co., Ltd. is a Japan-based global specialty pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4151) and majority-owned by Kirin Holdings Co., Ltd. The company develops and commercializes innovative biologics and gene therapies targeting unmet medical needs in hematology/oncology, rare diseases, nephrology, immunology/allergy, and neurology. Its core therapeutic assets include CRYSVITA (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia, POTELIGEO (mogamulizumab) for cutaneous T-cell lymphoma, KOMZIFTI (ziftomenib) for NPM1-mutant acute myeloid leukemia, and co-developed Romiplostim (Nplate) for immune thrombocytopenia and aplastic anemia. Underlying capabilities include advanced antibody engineering, hematopoietic stem cell gene therapy (via the January 2024 Orchard Therapeutics acquisition), and in-house biologics manufacturing at the Takasaki HB7 plant (completed April 2025) with additional U.S. capacity planned in Sanford, North Carolina.

The business operates a hybrid commercialization model. In Japan and select Asia Pacific markets, Kyowa Kirin sells directly through medical representatives to hospitals and specialty clinics. In the United States, KOMZIFTI is commercialized through a strategic partnership with Kura Oncology, while Romiplostim is co-developed with Amgen, generating approximately $385 million in Q4 2025 global sales (14% year-over-year growth). Outside the United States for ziftomenib, Kyowa Kirin leads development, regulatory, and commercialization. Revenue mechanics include direct product sales, milestone payments (e.g., $195 million paid to Kura in 2025, signaling reciprocal flow), royalties on partnered products, and licensing income (e.g., a €410 million-potential fibro-inflammatory disease deal with Boehringer Ingelheim). Pricing follows high-cost specialty and rare-disease reimbursement frameworks, with CRYSVITA publicly reimbursed across four Canadian provinces and federal programs, and KOMZIFTI priced at approximately $48,500 per month wholesale acquisition cost.

The pipeline is anchored in hematologic malignancies and rare diseases, with Phase 3 KOMET-017 evaluating frontline ziftomenib combinations and Orchard Therapeutics' OTL-201 advancing toward MPS-IIIA approval pathways. Strategic collaborations with Cimeio Therapeutics ($300 million cell therapy partnership) and Cowellnex/Metagen (microbiota testing joint venture) extend the modality footprint. The company holds dual CEO/COO leadership under President Abdul Mullick and restructured its International Region leadership in November 2025 with Julie Dehaene-Puype's appointment. Operations span Japan, North America (U.S. and Canada), the UK, France, Denmark, and Australia, employing between 5,001 and 10,000 people globally.

Name

Kyowa Kirin

Legal name

Kyowa Kirin Co., Ltd.

Website

https://kyowakirin.co.jp

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Kyowa Kirin is a Japan-based global specialty pharmaceutical company developing and commercializing biologics and gene therapies for hematology, oncology, rare diseases, nephrology, immunology, and neurology, serving patients across Japan, North America, EMEA, and Asia Pacific through direct sales and strategic partnerships with Amgen and Kura Oncology.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)

Keywords

• Specialty pharmaceuticals
• Biologic therapies
• Rare disease treatments
• Oncology drug development
• Nephrology medications

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Product Sales (Pharmaceuticals): Kyowa Kirin generates revenue through direct sales of proprietary pharmaceutical products including CRYSVITA (burosumab) for XLH, POTELIGEO (mogamulizumab) for cutaneous T-cell lymphoma, and other specialty drugs. Global romiplostim sales reached approximately $385 million in Q4 2025.
2. Collaboration & Licensing Milestones: The company receives milestone payments from partners including $195 million from Kura Oncology in 2025 (including $135 million for rapid delivery and $60 million from Phase 3 trial initiations). Additional collaboration payments of up to $315 million are anticipated under the Kyowa Kirin-Kura partnership.
3. Royalty Revenue from Partnered Products: Kyowa Kirin earns royalties on co-developed products including Romiplostim (Nplate) marketed by Amgen, with global sales showing 14% year-over-year growth in Q4 2025.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Kyowa Kirin is a Japan-based global specialty pharmaceutical company that researches, develops, manufactures, and commercializes innovative prescription medicines targeting unmet medical needs in four therapeutic areas: nephrology, oncology, immunology/allergy, and rare diseases. Its commercial portfolio includes proprietary biologics and small molecules such as CRYSVITA (burosumab), POTELIGEO (mogamulizumab), KOMZIFTI (ziftomenib), and Romiplostim (Nplate), distributed to hospitals, specialty clinics, and government healthcare systems worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• CRYSVITA (burosumab) CRYSVITA is a recombinant fully human monoclonal antibody (IgG1) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), used to treat X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) in adult and pediatric patients. Indicated for hospitals, specialty clinics, and academic medical centers treating rare metabolic bone diseases; publicly reimbursed for eligible adults in four Canadian provinces (Ontario, British Columbia, Saskatchewan, Alberta) and through the federal Non-Insured Health Benefits program.
• KOMZIFTI (ziftomenib) KOMZIFTI is an oral menin inhibitor approved by the FDA for adult patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). Commercialized by Kura Oncology in the United States and by Kyowa Kirin outside the U.S. Phase 3 KOMET-017 registrational trial is enrolling with potential for accelerated FDA review in 2028. Demonstrated 96% composite complete remission rate in NPM1-m patients and 90% in KMT2A-r patients.
• POTELIGEO (mogamulizumab) POTELIGEO is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4) approved for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome (cutaneous T-cell lymphoma). Sold to hospitals, hematology/oncology clinics, and academic medical centers treating blood cancers and lymphomas.
• Romiplostim / Nplate / Romiplate Romiplostim (marketed as Nplate / Romiplate) is a thrombopoietin receptor agonist (peptibody) co-developed with Amgen for the treatment of chronic immune thrombocytopenia (ITP) and aplastic anemia. Amgen leads global commercialization, with Kyowa Kirin receiving royalties on global sales (~14% YoY growth, ~$385M Q4 2025 sales). Distributed to hospitals, hematology clinics, and specialty pharmacies treating hematologic disorders.
• OTL-201 Gene Therapy OTL-201 is an investigational ex vivo hematopoietic stem cell (HSC) gene therapy developed by Orchard Therapeutics (a Kyowa Kirin subsidiary) for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA, Sanfilippo syndrome type A), an ultra-rare neurodegenerative lysosomal storage disorder. Granted UK MHRA Innovation Passport designation to facilitate accelerated development and access pathways.
• Duvroq (daprodustat)

Quantifiable outcome

• 94% 12-month overall survival rate in NPM1-mutant AML patients treated with ziftomenib + 7+3 chemotherapy
• +5 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered minor, core and major.

• CowellnexminorStrategic or Co-development Partner · 1 February 2026Joint venture between Kirin Holdings and Kyowa Kirin developing gut microbiota testing services and personalized food recommendation algorithms for Japanese individuals. Research leveraging shotgun metagenomic analysis data accumulated over approximately three years.
• Kura OncologycoreStrategic or Co-development Partner · 1 November 2025Global collaboration for ziftomenib (KOMZIFTI), a menin inhibitor for AML. Kyowa Kirin co-developed with Kura Oncology and received FDA approval in November 2025. Kyowa Kirin leads development, regulatory, and commercialization activities outside the United States, with Kura Oncology commercializing in the U.S. Kura received $195 million in milestone payments from Kyowa Kirin in 2025.
• Boehringer IngelheimmajorOEM/ Whitelabel/ Licensing Partner · 1 October 2025Exclusive worldwide license granted to Boehringer Ingelheim for a pre-clinical small molecule targeting fibro-inflammatory diseases. Deal valued at up to €410 million including milestone payments and royalties for development of new autoimmune and inflammatory therapies.
• AmgencoreStrategic or Co-development Partner · 1 January 2025Co-development partnership for Romiplostim (Nplate/Nplate), a thrombopoietin receptor agonist for chronic immune thrombocytopenia and aplastic anemia. Global romiplostim sales reached approximately $385 million in Q4 2025 with 14% year-over-year growth. Kyowa Kirin receives royalties on global sales.
• Cimeio TherapeuticsmajorStrategic or Co-development Partner · 1 December 2024$300 million collaboration to develop cell therapies for difficult-to-treat conditions. The partnership focuses on developing innovative cell therapy approaches leveraging Cimeio's proprietary technology platform.
• Orchard TherapeuticscoreStrategic or Co-development Partner · 1 January 2024Kyowa Kirin acquired UK-based Orchard Therapeutics in January 2024 for approximately £11m investment in UK drug manufacturing, strengthening its rare disease and gene therapy portfolio. Orchard Therapeutics operates as a Kyowa Kirin company focusing on hematopoietic stem cell gene therapies for rare diseases.
• Amgen (rocatinlimab)minorStrategic or Co-development Partner · 1 January 2023Partnership to advance rocatinlimab, an anti-OX40 monoclonal antibody for moderate-to-severe atopic dermatitis. Amgen terminated the collaboration in January 2026 and returned rights to Kyowa Kirin, which subsequently discontinued all clinical trials in March 2026 due to safety concerns (Kaposi's sarcoma cases).

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Astellas Pharma: Japanese specialty pharmaceutical company of similar scale with overlapping therapeutic areas including oncology, rare diseases, and biologics. Both are mid-cap Japanese pharma with global commercialization reach and strong biologics pipelines.
• Daiichi Sankyo: Major Japanese pharmaceutical company with strong oncology franchise and ADC platform. Comparable in therapeutic area focus (oncology, rare diseases) and Japanese-listed specialty pharma positioning with global commercial operations.
• Eisai: Japanese pharmaceutical company with significant neurology and oncology presence. Comparable in therapeutic area overlap (Parkinson's disease products, oncology pipeline) and Japanese-headquartered specialty pharma business model.
• Chugai Pharmaceutical: Japan-based specialty pharmaceutical company (Roche subsidiary) with strong antibody therapeutics platform. Directly comparable as a Japanese specialty pharma focused on biologics and antibody technology.
• BioMarin Pharmaceutical: US-based rare disease and gene therapy specialist. Comparable through shared focus on rare metabolic diseases (BioMarin has XLH treatments via Voxzogo competitor to CRYSVITA) and gene therapy platform investments analogous to Orchard Therapeutics.
• Swedish Orphan Biovitrum (Sobi): European specialty pharma focused on rare diseases and immunology. Comparable as a mid-cap rare disease specialist with biologics portfolio and global commercialization in hematology/immunology/rare diseases.
• UCB: Belgian specialty pharmaceutical company focused on immunology and neurology. Comparable through specialty pharma positioning, biologics focus, and overlap in immunology/inflammation therapeutic areas.

Broad incumbents

• Vertex Pharmaceuticals: Specialty biotech focused on rare diseases with strong commercial franchise and emerging gene therapy capabilities. Comparable through rare disease focus, biologics manufacturing expertise, and high-value specialty therapeutics pricing model.
• Alexion (AstraZeneca Rare Disease): Rare disease division of AstraZeneca with focus on hematology, nephrology, and metabolic rare diseases. Comparable through rare disease commercial model and therapeutic area overlap in nephrology and hematologic conditions.
• Takeda Pharmaceutical: Largest Japanese pharmaceutical company with global specialty and rare disease operations. Comparable as Japanese-headquartered global pharma with significant rare disease, oncology, and biologics franchise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/KyowaKirin_JP
• LinkedInlinkedin.com/company/kyowa-kirin-co-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kyowa Kirin